Safety and Pharmacokinetics of ODM-209
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Prostate Cancer Metastatic|Advanced Breast Cancer|Castration-resistant Prostate Cancer|Metastatic Breast Cancer
Interventions: DRUG: ODM-209
Sponsor: Orion Corporation, Orion Pharma